Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab
Alemtuzumab is usually associated with opportunistic infections. We have treated 67 patients, 8 non-Hodgkin’s lymphoma and 59 chronic lymphocytic leukemia (CLL) with campath. Among CLL patients, 6 used alemtuzumab in first line, alone or with chemotherapy, 41 as consolidation therapy and 11 as salva...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Ferrata Storti Foundation
2008-02-01
|
| Rangatū: | Haematologica |
| Urunga tuihono: | https://haematologica.org/article/view/4768 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|